Deals this week: Zensun Sci & Tech Co Ltd, Onconova Therapeutics Inc

24th November 2017 (Last Updated November 24th, 2017 00:00)

Zensun Sci & Tech Co Ltd has secured $76.5m in funding from SDIC Venture Capital Management, China Venture Capital Co Ltd, Orient Securities Co Ltd, TFTR Investment and Everbright Ivy Capital Investment Company in private placement of shares.

Zensun Sci & Tech Co Ltd has secured $76.5m in funding from SDIC Venture Capital Management, China Venture Capital Co Ltd, Orient Securities Co Ltd, TFTR Investment and Everbright Ivy Capital Investment Company in private placement of shares.

Headquartered in China, Zensun Sci & Tech is a biopharmaceutical company that offers treatment for cardiovascular disorders.

The company plans to invest the funds for the construction of a new research centre and the research and development of a cardiovascular drug called Neucardin.

Onconova Therapeutics Inc plans to raise $84.54m in a public issue of shares of its common stock, preferred stock, debt securities, warrants and units.

Based in the US, Onconova is a novel small molecule cancer treatment drug developer.

The company’s selling stakeholders simultaneously intend to issue 100 shares priced at $1.67 each.

The proceeds are intended to be used for enhancing the company’s clinical and pre-clinical programmes and research and development activities, and general corporate purposes.

Acasti Pharma Inc has signed a non-binding term sheet agreement with a Chinese pharmaceutical firm to enhance and commercialize CaPre.

"The latest funding increases the total proceeds raised by the company to €14.5m."

Canadian firm Acasti involves in the research and development of pharmaceutical products for the prevention and treatment of cardiometabolic disorders.

The omega-3 phospholipid substrate CaPre is extracted from krill oil and is used to treat cardiovascular disease and pancreatitis.

Mezzion Pharma Co Ltd intends to raise $4.15m by ofering 130,000 shares of common stock priced at $31.97 a share to public.

Headquartered in South Korea, Mezzion Pharma is involved in the development, licensing and commercialisation of drugs for the treatment of erectile dysfunction and benign prostatic hyperplasia.

Step Pharma SAS has further secured €8.6m $10.1m from Kurma Partners SA, Pontifax Ltd, Bpifrance, Inserm Transfert Initiative, IDInvest Partners, Sygnature Discovery Ltd and Imagine Institute in a series A financing round.

The latest funding increases the total proceeds raised by the company to €14.5m ($17m).

Step Pharma raised $6.9m from Kurma Partners SA in series A financing round held on 31 July 2016.

The firm plans to use the additional funding for the further development of its oral immunomodulators targeting cytidine triphosphate synthase 1.